StreetInsider.com After-Hours Movers 05/31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
StreetInsider.com After-Hours Movers:
CKX Inc. (Nasdaq: CKXE) 31.7% HIGHER; Reports from the Wall Street Journal, CKX Inc. is in negotiations to be taken private by its largest shareholder Robert Sillerman. A deal could be worth $14 per share.
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) 13% HIGHER; announced positive results from the preliminary analysis of the Company's Phase IIb clinical study of ecabet sodium, which is being developed as a treatment for dry eye syndrome.
OmniVision Technologies, Inc. (Nasdaq: OVTI) 8.9% HIGHER; reports Q4 non-GAAP EPS of $0.06 (ex-items), 7 cents better than estimates. Revenues were $119.2 million vs. $105.21 million consensus. Sees Q2 revenues of $155 to $165 million, versus the consensus of $117.8 million. Sees Q2 EPS of $0.13-$0.21, versus the consensus of $0.06.
Nektar Therapeutics (Nasdaq: NKTR) 8% HIGHER; sees FY07 revenues between $236-276 million vs. prior guidance of $210-250 million vs. consensus of $249.53 million.
Immucor, Inc. (Nasdaq: BLUD) 7% LOWER; expects revenues for the fiscal year ending May 31, 2008 to range from $249 million to $257 million. The company expect to generate earnings per diluted share in the range of $0.92 to $0.96 for fiscal year 2008. The company also announced that CFO Patrick Waddy will resign effective August 31, 2007 in order to live full-time with his family in Canada.
Dell (NASDAQ: DELL) 5% HIGHER; reported Q1 earnings of $0.34 per share, versus the consensus of $0.26. Revenues came in at $14.6 billion versus the consensus of $13.95 billion. Q1 gross margins at 19.5%.
J. Crew (NYSE: JCG) 5% HIGHER' reported Q1 earnings of $0.39 per share, 9 cents better than estimates. (0.30) Revenues came in at $297.3 million versus the consensus of $271.1 million. Raises FY EPS guidance. Sees FY EPS of $1.37-$1.41, versus prior view of $1.27-$1.31 and the consensus of $1.32.
DexCom, Inc. (NASDAQ: DXCM) 4.4% HIGHER; has received Food and Drug Administration (FDA) approval for SEVEN, its 7-Day STS Continuous Glucose Monitoring System. SEVEN is DexCom's second generation device designed to help people with diabetes better manage their diabetes and control their glucose levels.
CKX Inc. (Nasdaq: CKXE) 31.7% HIGHER; Reports from the Wall Street Journal, CKX Inc. is in negotiations to be taken private by its largest shareholder Robert Sillerman. A deal could be worth $14 per share.
ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) 13% HIGHER; announced positive results from the preliminary analysis of the Company's Phase IIb clinical study of ecabet sodium, which is being developed as a treatment for dry eye syndrome.
OmniVision Technologies, Inc. (Nasdaq: OVTI) 8.9% HIGHER; reports Q4 non-GAAP EPS of $0.06 (ex-items), 7 cents better than estimates. Revenues were $119.2 million vs. $105.21 million consensus. Sees Q2 revenues of $155 to $165 million, versus the consensus of $117.8 million. Sees Q2 EPS of $0.13-$0.21, versus the consensus of $0.06.
Nektar Therapeutics (Nasdaq: NKTR) 8% HIGHER; sees FY07 revenues between $236-276 million vs. prior guidance of $210-250 million vs. consensus of $249.53 million.
Immucor, Inc. (Nasdaq: BLUD) 7% LOWER; expects revenues for the fiscal year ending May 31, 2008 to range from $249 million to $257 million. The company expect to generate earnings per diluted share in the range of $0.92 to $0.96 for fiscal year 2008. The company also announced that CFO Patrick Waddy will resign effective August 31, 2007 in order to live full-time with his family in Canada.
Dell (NASDAQ: DELL) 5% HIGHER; reported Q1 earnings of $0.34 per share, versus the consensus of $0.26. Revenues came in at $14.6 billion versus the consensus of $13.95 billion. Q1 gross margins at 19.5%.
J. Crew (NYSE: JCG) 5% HIGHER' reported Q1 earnings of $0.39 per share, 9 cents better than estimates. (0.30) Revenues came in at $297.3 million versus the consensus of $271.1 million. Raises FY EPS guidance. Sees FY EPS of $1.37-$1.41, versus prior view of $1.27-$1.31 and the consensus of $1.32.
DexCom, Inc. (NASDAQ: DXCM) 4.4% HIGHER; has received Food and Drug Administration (FDA) approval for SEVEN, its 7-Day STS Continuous Glucose Monitoring System. SEVEN is DexCom's second generation device designed to help people with diabetes better manage their diabetes and control their glucose levels.
You May Also Be Interested In
- After-Hours Movers: QCOM, COHR, APP, HUBS, SNAP, FSLY, FIG, ZG, BROS, CDE
- Dutch Bros plummets on slowing sales, cut EBITDA outlook
- OpenAI to acquire Pierre to expand Codex developer infrastructure
Create E-mail Alert Related Categories
General News, Special ReportsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
